<DOC>
	<DOCNO>NCT00742261</DOCNO>
	<brief_summary>Study compare 2 different chemical form GSK1363089 .</brief_summary>
	<brief_title>A Study Investigate Bioavailability Two Forms GSK1363089 Subjects With Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Histologically cytologically confirm diagnosis solid tumor malignancy . 18 year old ECOG 01. female subject pregnant Male subject must agree use contraception method Able swallow retain oral medication . The subject refrain use illicit drug adhere protocolstated restriction participate study . QTcB QTcF &lt; 470 msec . Bilirubin = 1.5mg/dl , AST , ALT , ALP &lt; 2X ULN absence malignant disease liver &lt; 5X ULN case liver involvement tumor . Serum Creatinine &lt; 1.5mg/dL Exclusion Inclusion : The subject receive anticancer treatment . The subject participate clinical trial receive investigational product within 21 day . The subject know brain metastasis . The subject uncontrolled intercurrent illness . History sensitivity study medication , component . The subject know positive human immunodeficiency virus ( HIV ) . Subjects partial complete gastrectomy . Pregnant female determine positive ÃŸhCG test screen prior dosing . Lactating female . Unwillingness inability follow procedure outline protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Safety</keyword>
	<keyword>MET</keyword>
	<keyword>Bioavailability</keyword>
	<keyword>Patients</keyword>
	<keyword>GSK1363089A</keyword>
	<keyword>GSK1363089G</keyword>
	<keyword>GSK1363089</keyword>
	<keyword>Relative</keyword>
</DOC>